Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from ...

Sometimes diet and exercise are not enough to help the 100 million Americans with obesity lose weight and prevent health ...

Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster ...

Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes ...

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive ...

Roche Holding AG said side effects in a highly anticipated study of its experimental obesity pill were milder when it eased ...

Novo Nordisk's shares dropped nearly 5% after their experimental obesity pill, monlunabant, showed underwhelming Phase 2a trial results. The pill, acquired through a $1 billion deal with Inversago ...

Novo Nordisk’s NVO oral obesity pill, amycretin, showed faster weight loss than its blockbuster weekly injection, Wegovy (semaglutide), in a phase I study. Not only did NVO’s stock rise 4% in ...

An experimental obesity pill being developed by Ozempic-maker Novo Nordisk showed only limited additional weight loss when taken in higher doses compared to the lowest dose tested in a mid-stage ...